University of California, Los Angeles |
Sophie Deng |
Late Stage Preclinical Projects |
Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy |
$4,244,211 |
IQVIA, Inc. |
Peter Robinson |
Accelerating Center |
An Accelerating Center designed to expedite the development and delivery of high quality stem cell therapies to patients |
$11,772,453 |
University of California, Los Angeles |
Brigitte Gomperts |
Conference - Lung Regenerative Medicine Workshop |
Stem Cells for Lung Diseases - Overcoming Barriers to Find New Therapies |
$44,548 |
Children's Hospital of Los Angeles |
Senta Georgia |
Inception - Discovery Stage Research Projects |
Developing a personalized approach to beta cell replacement for patients with a genetic form of diabetes |
$179,995 |
University of California, San Diego |
Karl Wahlin |
Inception - Discovery Stage Research Projects |
Microenvironment based optimization of retinal induction using CRISPR-CAS9 reporter pluripotent stem cells as an expandable source of retinal progenitors and photoreceptors. |
$232,200 |
University of California, Los Angeles |
Stanley Carmichael |
Inception - Discovery Stage Research Projects |
iPS-Interneuron Transplantation for Neural Repair after Stroke |
$229,396 |
Stanford University |
Bertha Chen |
Inception - Discovery Stage Research Projects |
Autologous iPSC-based therapy for radiation induced bladder injury |
$235,836 |
University of California, San Diego |
Dionicio Siegel |
Inception - Discovery Stage Research Projects |
New Methods for the Chemical Expansion of Hematopoietic Stem and Progenitor Cells |
$232,200 |
Stanford University |
Philip Beachy |
Inception - Discovery Stage Research Projects |
Curing bladder cancer by replacing corrupted urothelium with differentiated hES cells |
$210,906 |
University of California, Berkeley |
Jacob Corn |
Inception - Discovery Stage Research Projects |
Genome editing for causation and reversion of MPN-associated mutations in human hematopoietic stem cells |
$235,800 |
University of California, Los Angeles |
Arjun Deb |
Inception - Discovery Stage Research Projects |
Targeting progenitors in scar tissue to reduce chronic scar burden |
$230,400 |
University of California, San Francisco |
Holger Willenbring |
Inception - Discovery Stage Research Projects |
Generation of bile duct-competent transplantable human liver organoids |
$206,460 |
Cedars-Sinai Medical Center |
Linda Cambier |
Inception - Discovery Stage Research Projects |
Exosomal Y-RNAs as mediators of bioactivity of cardiac-derived cell therapy |
$181,063 |
Cedars-Sinai Medical Center |
Clive Svendsen |
Inception - Discovery Stage Research Projects |
Blood Brain Barrier (BBB)-on-Chip: Development and validation of a novel iPS-based microfluidic model of the human BBB |
$241,992 |
Stanford University |
Phillip Yang |
Inception - Discovery Stage Research Projects |
Activation of patient-specific endogenous myocardial repair through the exosomes generated from the hypoxic iPSC-derived cardiomyocytes (iCMs). |
$234,619 |
University of California, Los Angeles |
Bennett Novitch |
Inception - Discovery Stage Research Projects |
Organoid Modeling of Human Cortical Microcircuits |
$208,916 |
Stanford University |
Albert Wong |
Therapeutic Translational Research Projects |
2nd Generation Vaccine for the Treatment of Glioblastoma |
$2,929,889 |
University of California, San Francisco |
Andrew Brack |
Inception - Discovery Stage Research Projects |
Examining the efficacy of GDF11 antibody as a rejuvenator of aged human muscle stem cell capacity and muscle repair . |
$180,000 |
University of California, Los Angeles |
April Pyle |
Inception - Discovery Stage Research Projects |
Novel Platforms to Enhance In Vivo Delivery of Skeletal Muscle Progenitor Cells from Human Pluripotent Stem Cells |
$230,400 |
University of California, San Diego |
Alysson Muotri |
Inception - Discovery Stage Research Projects |
Reverse transcriptase inhibitors as a novel therapeutic approach for neurological autoimmune disorders |
$210,060 |
University of California, Los Angeles |
Owen Witte |
Inception - Discovery Stage Research Projects |
Identification of stem cell surface markers as potential therapeutic targets for advanced prostate cancer |
$209,160 |
Stanford University |
Jeffrey Goldberg |
Inception - Discovery Stage Research Projects |
Embryonic Stem Cells for Corneal Endothelial Degeneration |
$235,836 |
Vitalant Research Institute |
Marcus Muench |
Inception - Discovery Stage Research Projects |
Modulating Liver Sinusoidal Endothelial Cell Permeability to Enhance Engraftment of Endothelial Cell Progenitors for the Treatment of Hemophilia A |
$180,000 |
University of California, Irvine |
LESLIE Thompson |
Conference II |
HD-CARE INAUGURAL SYMPOSIUM |
$1,500 |
International Society for Experimental Hematology |
David Traver |
Conference II |
International Society for Experimental Hematology, 45th Annual Scientific Meeting |
$25,000 |
American Association of Blood Banks |
Naynesh Kamani |
Conference II |
14th International Cord Blood Symposium: Give Life Twice |
$15,000 |
Keystone Symposia on Molecular and Cellular Biology |
Thale Jarvis |
Conference II |
Neurogenesis during Development and in the Adult Brain (joint with Transcriptional and Epigenetic Control in Stem Cells) |
$35,000 |
University of California, San Francisco |
Jennifer Puck |
Late Stage Preclinical Projects |
Ex Vivo Transduction of the Human Artemis (DCLRE1C) cDNA by Lentiviral Vector AProArt into CD34+ Hematopoietic Cells for Artemis (ART)-Deficient Severe Combined Immunodeficiency (SCID) |
$4,268,865 |
Children's Hospital of Los Angeles |
Mark Frey |
Therapeutic Translational Research Projects |
ASCENT- Advanced Stem Cell Enteric Neuropathy Therapy |
$7,077,352 |
University of California, Davis |
Joseph Anderson |
Therapeutic Translational Research Projects |
Overexpression of HexA/HexB by lentivector expression in blood cells to treat Tay-Sachs and Sandhoff disease |
$883,174 |
University of California, Los Angeles |
Peter Butler |
Therapeutic Translational Research Projects |
Personalized Cell Therapy for Diabetes |
$1,494,896 |
City of Hope, Beckman Research Institute |
Yanhong Shi |
Therapeutic Translational Research Projects |
Process development for establishing an iPSC-based therapeutic candidate for Canavan disease |
$7,377,384 |
Capricor, Inc |
Linda Marban |
Clinical Trial Stage Projects |
Allogeneic Cardiosphere-Derived Cells for Duchenne Muscular Dystrophy Cardiomyopathy |
$3,376,259 |
University of California, Los Angeles |
Lili Yang |
Therapeutic Translational Research Projects |
Stem Cell-Based iNKT Cell Therapy for Cancer |
$6,956,775 |
University of California, San Diego |
Lawrence Goldstein |
Therapeutic Translational Research Projects |
Human Embryonic Stem Cell-Derived Neural Stem Cell Transplants in Amyotrophic Lateral Sclerosis |
$1,790,000 |
Semma Therapeutics |
Felicia Pagliuca |
Therapeutic Translational Research Projects |
Personalized Cell Therapy for Diabetes |
$597,333 |
Mosaic Event Management, Inc. |
Ron Johnson |
Conference - Manage The 2016 Bridges And SPARK Annual Meetings |
2016 CIRM Bridges & SPARK Meetings |
$205,388 |
Angiocrine Bioscience, Inc. |
Paul Finnegan |
Late Stage Preclinical Projects |
Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy |
$3,797,117 |
University of California, San Diego |
Catriona Jamieson |
Conference - The 2016 Alpha Stem Cell Clinic Annual Symposium |
UCSD Division of Regenerative Medicine and CIRM Alpha Clinics Network Symposium |
$37,778 |
The University Corporation at California State University, Northridge |
Cindy Malone |
Bridges |
Stem Cell Scientist Training Program |
$2,732,149 |
Cal State Univ, San Bernadino |
Nicole Bournias-Vardiabasis |
Bridges |
Stem Cell Scholars- from Basic Research to Clinical Translation: training a diverse pool of students in the lab, engaging them in patient and healthcare activities, motivating them to educate their immediate community and enabling them for careers in ... |
$2,659,136 |
City of Hope, Beckman Research Institute |
Paul Salvaterra |
SPARK |
SPARK Award Program in Stem Cell Biology for California High School Students |
$241,080 |
UCSF Benioff Children’s Hospital Oakland |
Ellen Fung |
SPARK |
Leveraging Investment in hiGHschool Training: Summer Program to Accelerate Regenerative medicine Knowledge (LIGHT a SPARK) |
$226,519 |
California State University San Marcos Corporation |
Bianca Mothe |
Bridges |
CIRM Bridges to Stem Cell Research and Therapy Training Grant |
$2,936,474 |
Cedars-Sinai Medical Center |
Wafa Tawackoli |
SPARK |
Mentored High School Summer Research Program |
$296,628 |
San Diego State University Foundation |
Ralph Feuer |
Bridges |
Bridges to Stem Cell Research Internship Program |
$2,934,578 |
University of California, Davis |
Gerhard Bauer |
SPARK |
Internship at a Cutting Edge CIRM-funded Stem Cell Research Facility |
$360,573 |
California State University, Channel Islands |
Nitika Parmar |
Bridges |
CIRM Graduate Student Training Grant for the Implementation of a Stem Cell Technology and Lab Management Program: Training in Stem Cell Sciences and Regenerative Medicine |
$2,925,187 |
University of California, San Francisco |
Katherine Nielsen |
SPARK |
Developing High School Students' Research Practices and Regenerative Medicine Knowledge through a Summer Intern Program |
$382,430 |
Cal State Univ, Fullerton |
Nilay Patel |
Bridges |
Bridges to Stem Cell Research, Therapy and Careers: A Talent Development Program for Training Diverse Undergraduates for Careers in Regenerative Medicine |
$2,854,530 |
Stanford University |
Paul Utz |
SPARK |
Stem Cell and Regenerative Medicine- Summer Research Internship |
$350,482 |
Cal State Univ, Long Beach |
Lisa Klig |
Bridges |
CIRM Stem Cell Biotechnology Training Program |
$2,919,901 |
California Institute of Technology |
Henry Lester |
SPARK |
CIRM Early Investigators High School Stem Cell Research Program |
$132,717 |
Cal Poly Corporation, an Auxiliary of California Polytechnic State University, San Luis Obispo |
Trevor Cardinal |
Bridges |
Interdisciplinary Master of Science Program in Regenerative Medicine |
$2,556,199 |
Cal State Univ, Sacramento |
Lisa Hammersley |
Bridges |
Strengthening the Pipeline of Master's-level Scientific and Laboratory Personnel in Stem Cell Research |
$1,894,970 |
San Francisco State University |
Lily Chen |
Bridges |
CIRM Bridges 2.0: Training the Next Generation of Stem Cell Scientists |
$2,958,876 |
SJSU Research Foundation |
Tzvia Abramson |
Bridges |
SCILL- Stem Cell Internships in Laboratory-based Learning |
$2,916,283 |
Humboldt State University Sponsored Programs Foundation |
Jacob Varkey |
Bridges |
CIRM 2.0 Bridges Training Program |
$2,534,223 |
Pasadena City College |
Pamela Eversole-Cire |
Bridges |
Bridges to Stem Cell Research and Therapy at Pasadena City College |
$2,414,873 |
City College Of San Francisco |
Carin Zimmerman |
Bridges |
Stem Cell Training Enhancement Program with a focus on Translational Research |
$2,000,258 |
University of California, San Diego |
John Ravits |
Conference II |
California ALS Research Summit 2016 |
$11,400 |
University of California, Los Angeles |
Donald Kohn |
Conference II |
Primary Immune Deficiency Treatment Consortium (PIDTC) Annual Scientific Workshop |
$29,807 |
City of Hope, Beckman Research Institute |
Fouad Kandeel |
Conference II |
2016 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium |
$10,000 |
Gordon Research Conferences |
Ophir Klein |
Conference II |
2016 Gordon Research Conference on Craniofacial Morphogenesis and Tissue Regeneration |
$5,000 |
Stanford University |
Joseph Wu |
Conference II |
Drug Discovery & Stem Cell Models for Cardiovascular Disease Conference |
$7,500 |
ImmunoCellular Therapeutics |
Anthony Gringeri |
Clinical Trial Stage Projects |
A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy |
$5,391,016 |
University of California, Irvine |
Sidney Golub |
Conference II |
Human Research In Times of Controversy: From Stem Cells To Fetal Tissue |
$13,562 |
Sanford Consortium for Regenerative Medicine |
Edward Holmes |
Conference II |
Stem Cell Meeting on the Mesa |
$50,000 |
Alliance Forum Foundation |
George Hara |
Conference II |
2015 World Alliance Forum in San Francisco (2015 WAFSF) "Regenerative Medicine: Let's Talk Business!" |
$10,000 |
Calibr |
Peter Schultz |
Late Stage Preclinical Projects |
Development of a Chondrogenic Drug Candidate Targeting Resident Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$1,667,832 |
University of California, Los Angeles |
Donald Kohn |
Clinical Trial Stage Projects |
A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease |
$7,083,364 |
University of California, Davis |
Mehrdad Abedi |
Clinical Trial Stage Projects |
Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients |
$8,414,265 |
Cedars-Sinai Medical Center |
Shaomei Wang |
Late Stage Preclinical Projects |
IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa |
$4,954,514 |
Caladrius Biosciences |
Robert Dillman |
Clinical Trial Stage Projects |
Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial. |
$3,000,000 |
Salk Institute for Biological Studies |
David Schubert |
Preclinical Development Awards |
Human Stem-Cell Based Development of a Potent Alzheimer’s Drug Candidate |
$1,664,885 |
University of California, Irvine |
Leslie Thompson |
Preclinical Development Awards |
A hNSC Development Candidate for Huntington’s Disease |
$4,951,623 |
Calibr |
Peter Schultz |
Preclinical Development Awards |
Development of a Chondrogenic Drug Candidate Targeting Cartilage-residing Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$2,306,703 |
University of California, Davis |
Diana Farmer |
Preclinical Development Awards |
Placental Stem Cells for the In Utero Treatment of Spina Bifida |
$2,182,146 |
University of California, Davis |
Roslyn Isseroff |
Preclinical Development Awards |
Scaffold for dermal regeneration containing pre-conditioned mesenchymal stem cells to heal chronic diabetic wounds |
$4,620,144 |
Scripps Health |
Darryl D'Lima |
Preclinical Development Awards |
Embryonic Stem Cell-Derived Chondroprogenitor Cells to Repair Osteochondral Defects |
$7,660,211 |
Stanford University |
Matthew Porteus |
Preclinical Development Awards |
Pre-clinical development of gene correction therapy of hematopoietic stem cells for SCID-X1 |
$874,877 |
Vitalant Research Institute |
Shibani Pati |
Conference |
Cellular Therapies in Trauma and Critical Care Medicine: Forging New Frontiers |
$40,000 |
University of Southern California |
Qing Liu-Michael |
Conference |
USC/UCSF/UCLA Tri-Institutional Stem Cell Retreat |
$5,000 |
Ocular Research Symposia Foundation, Inc. |
Gerald Chader |
Conference |
SIGHT RESTORATION THROUGH STEM CELL THERAPY |
$20,000 |
Stanford University |
Joseph Wu |
Conference |
Cardiovascular Tissue Engineering Symposium |
$25,000 |
University of California, Davis |
Randi Hagerman |
Conference |
Pathways of Neurodevelopmental Disorders (C8) |
$29,939 |
Stanford University |
Anthony Oro |
Tools and Technologies III |
A Chromatin Context Tool for Predicting iPS Lineage Predisposition and Tissue Graftability |
$1,391,125 |
University of California, San Francisco |
Andrew Leavitt |
Tools and Technologies III |
Small molecule tools and scale-up technologies to expand human umbilical cord blood stem and progenitor cells for clinical and research use |
$1,416,600 |
University of California, San Diego |
Shaochen Chen |
Tools and Technologies III |
Development of 3D Bioprinting Techniques using Human Embryonic Stem Cells Derived Cardiomyocytes for Cardiac Tissue Engineering |
$1,368,264 |
Stanford University |
Joseph Wu |
Tools and Technologies III |
Macaca mulatta as advanced model for predictive preclinical testing of engineered cardiac autografts and allografts |
$1,689,744 |
University of California, Berkeley |
David Schaffer |
Tools and Technologies III |
Engineered Biomaterials for Scalable Manufacturing and High Viability Implantation of hPSC-Derived Cells to Treat Neurodegenerative Disease |
$1,239,276 |
University of California, Los Angeles |
Carla Koehler |
Tools and Technologies III |
A small molecule tool for reducing the malignant potential in reprogramming human iPSCs and ESCs |
$1,283,900 |
University of California, San Diego |
Shyni Varghese |
Tools and Technologies III |
Technologies to improve in vivo function of transplanted stem cells |
$1,373,683 |
Scripps Research Institute |
Jeanne Loring |
Tools and Technologies III |
User-friendly predictive molecular diagnostic assays for quality control of stem cell derivatives for transplantation and drug discovery |
$1,728,390 |
University of California, Los Angeles |
Leif Havton |
Tools and Technologies III |
Development of a Relevant Pre-Clinical Animal Model as a Tool to Evaluate Human Stem Cell-Derived Replacement Therapies for Motor Neuron Injuries and Degenerative Diseases |
$1,308,711 |
University of California, Los Angeles |
James Dunn |
Tools and Technologies III |
Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction |
$1,044,423 |
University of California, Davis |
J. Leach |
Tools and Technologies III |
Multi-modal technology for non-destructive characterization of bioengineered tissues |
$1,574,151 |
University of California, Davis |
Laura Marcu |
Tools and Technologies III |
Multimodal platform combining optical and ultrasonic technologies for in vivo nondestructive evaluation of engineered vascular tissue constructs |
$1,834,350 |
Stanford University |
Fan Yang |
Tools and Technologies III |
Injectable Macroporous Matrices to Enhance Stem Cell Engraftment and Survival |
$1,434,235 |
Stanford University |
Sarah Heilshorn |
Tools and Technologies III |
Injectable Hydrogels for the Delivery, Maturation, and Engraftment of Clinically Relevant Numbers of Human Induced Pluripotent Stem Cell-Derived Neural Progenitors to the Central Nervous System |
$1,347,767 |